Bardoxolone methyl + Placebo
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Kidney Disease
Conditions
Diabetic Kidney Disease
Trial Timeline
May 30, 2018 → Jul 31, 2023
NCT ID
NCT03550443About Bardoxolone methyl + Placebo
Bardoxolone methyl + Placebo is a phase 3 stage product being developed by Kyowa Kirin for Diabetic Kidney Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT03550443. Target conditions include Diabetic Kidney Disease.
What happened to similar drugs?
20 of 20 similar drugs in Diabetic Kidney Disease were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04018339 | Phase 1 | Completed |
| NCT03550443 | Phase 3 | Terminated |
Competing Products
20 competing products in Diabetic Kidney Disease